Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS Overlap or High-Risk CMML

NCT06523556 is registered in ClinicalTrials.gov with Uma Borate as lead sponsor.

NCT NCT06523556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06523556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS Overlap or High-Risk CMML
Lead sponsor
Uma Borate
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 2, 2024
Completion date
October 31, 2028
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical chronic myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic/myeloproliferative neoplasm, recurrent myelodysplastic/myeloproliferative neoplasm, recurrent myeloproliferative neoplasm, refractory chronic myelomonocytic leukemia, refractory myelodysplastic/myeloproliferative neoplasm, refractory myeloproliferative neoplasm